Notes

A Case Series of Radiation-induced Hemorrhagic Gastroduodenitis.
g in the rates between Jews and Arabs over time may indicate shared environmental factors.
Systems biology is a rapidly advancing field of science that allows us to look into disease mechanisms, patient diagnosis and stratification, and drug development in a completely new light. It is based on the utilization of unbiased computational systems free of the traditional experimental approaches based on personal choices of what is important and what select experiments should be performed to obtain the expected results.

Systems biology can be applied to inflammatory bowel disease (IBD) by learning basic concepts of omes and omics and how omics-derived "big data" can be integrated to discover the biological networks underlying highly complex diseases like IBD. Once these biological networks (interactomes) are identified, then the molecules controlling the disease network can be singled out and specific blockers developed.

The field of systems biology in IBD is just emerging, and there is still limited information on how to best utilize its power to advance our understanding of Crohn disease and ulcerative colitis to develop novel therapeutic strategies. Few centers have embraced systems biology in IBD, but the creation of international consortia and large biobanks will make biosamples available to basic and clinical IBD investigators for further research studies.

The implementation of systems biology is indispensable and unavoidable, and the patient and medical communities will both benefit immensely from what it will offer in the near future.
The implementation of systems biology is indispensable and unavoidable, and the patient and medical communities will both benefit immensely from what it will offer in the near future.
The novel oral nucleoside antineoplastic agent trifluridine/tipiracil was approved for metastatic colorectal cancer in Japan in March 2014. In this post-marketing surveillance study, we investigated the safety and efficacy of trifluridine/tipiracil in a real-world setting, particularly haematological drug reactions classified according to the baseline renal and hepatic functions.

We investigated patients with metastatic colorectal cancer who received trifluridine/tipiracil during the first four treatment cycles prospectively. The patients typically received 35mg/m2 trifluridine/tipiracil twice daily on days 1-5 and 8-12 every 28days. The primary objective was to assess the safety of trifluridine/tipiracil, but its efficacy was also evaluated.

Between July 2014 and June 2016, 860 patients were enrolled in the study, and the safety and efficacy of trifluridine/tipiracil were evaluated in 823 patients. Adverse drug reactions occurred in 89.7% of the patients. The most common adverse drug reactions were decreased white blood cell count (67.0%) and neutrophil count (63.9%). Haematological drug reactions of grade ≥3 were observed in 41.7% of the patients with normal renal function; 50.3, 65.6 and 78.9% of the patients had mild, moderate and severe renal impairments, respectively. Hepatic impairment was not associated with a higher incidence of haematological drug reactions. The median overall survival was 8.4months, with a 1-year survival rate of 33.7%.

This post-marketing surveillance study further confirmed the safety and tolerability profile of trifluridine/tipiracil observed in a clinical study setting.
This post-marketing surveillance study further confirmed the safety and tolerability profile of trifluridine/tipiracil observed in a clinical study setting.In April 2016, the Japanese government introduced health technology assessment as a response to rising medical expenses due to 'medical innovation'. This study investigates how Japanese breast cancer patients who received treatment in Japan consider the financial value (willingness-to-pay; WTP) for their life and health by using the contingent valuation method (CVM) prospectively. First, 168 patients (84 primary breast cancer patients and 84 metastatic breast cancer patients) were pre-examined their WTP with dichotomous-choice method survey form. EPZ020411 Next, 1,596 patients (798 primary breast cancer patients and 798 metastatic breast cancer patients) will be surveyed to their WTP for hypothetical scenarios in CVM. Based on our results, we will construct an evaluation axis from the patients' viewpoint for the cost-effectiveness of clinical trials to establish standard treatments for breast cancer. We believe this research can contribute to create a meaningful healthcare system for patients, clinicians, industries, and healthcare policymakers.The purpose of this minireview is to build a bridge between two research fields surface-enhanced resonant Raman spectroscopy (SERRS) under near-single-molecule conditions and the branch of plasmonics treating strong coupling between plasmons and molecular excitons. SERRS enables single-molecule spectroscopy owing to its significant enhancement at SERRS hotspots (HSs), localized at gaps or junctions between plasmonic nanoparticle aggregates. SERRS is SERS (surface enhanced Raman spectroscopy) under a resonant Raman excitation condition. The origin of the Raman enhancement in SERRS is electromagnetic coupling between plasmons and molecular excitons at HSs. It has been reported that the coupling energy at HSs reaches the strong coupling region, meaning that they are potential platforms for applications of single molecular excitons modified by strong coupling. In this review, we discuss recent progress related to electronic strong coupling in near-single-molecule SERRS collective (e.g., vibrational) strong coupling is out of the scope of this minireview. First, we explain the relationship between the electromagnetic enhancement factor and coupling energy. Second, we introduce three theoretical methods for obtaining evidence of strong coupling at HSs. Third, we discuss a method for reproducing enhanced and modified molecular Raman and fluorescence spectra at HSs using the coupling energy. Finally, we propose the use of two experimental methods of absorption spectroscopy at HSs for modifying molecular electronic dynamics by strong coupling and comment on future applications of SERRS HSs to photophysics and photochemistry.
Website: https://www.selleckchem.com/products/epz020411.html